WEST GREENWICH – Amgen Inc. on Tuesday reported fourth-quarter earnings of $767 million despite declining sales for Enbrel, the rheumatoid-arthritis drug that is manufactured locally. The biotech company based in Thousand Oaks, Calif., said in its quarterly statement Enbrel sales in the fourth quarter fell 8% year over year to $1.015 billion, falling short of
Already a Subscriber? Log in
To Continue Reading This Article
Become a Providence Business News subscriber and get immediate access to all of our premier content and much more.Learn More and Become a Subscriber
- Critical RI business news and analysis updated daily.
- 1 year of print (26 issues).
- Unlimited access to all subscriber only content on our website, on any device.
- Free email alerts.
- Annual Book of Lists Print Edition.
- All special issues produced during subscription term.
Click Here to purchase a paywall bypass link for this article
PBN Branded Content
Your Business Has Gone Global. Has Your Insurance?
A decade ago, “doing business internationally” was mostly a large-company concern. Today, a manufacturer in…
Learn More
